COMPANY PROFILE

SynOx Therapeutics

Explore full profile

Our mission is to focus on the unmet clinical needs of patients suffering from Tenosynovial Giant Cell Tumours (TGCT)

Dublin, IrelandFounded 2020Biotech & Life Sciences

Valuation $250–500M Last recorded · 2024

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About SynOx Therapeutics

SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (TGCT) and other indications. SynOx is backed by a strong investor syndicate with long and successful backgrounds in building biopharma companies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2020
Headquarters: Dublin, Ireland
Employees: 32
Open positions: None listed
Dealroom signal: 85.9/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Pharmacy, Biotechnology, Cellular, Immunotherapy, Tech for Biotech and Pharma, Biotech and Pharma, proteomics, science-based
Business model: Manufacturing
Client focus: b2c
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
DEBTDebt	Apr 2024	$35M	—	Hercules Capital	↗
SERIES BOther financing	Apr 2024	$77M	$310M	Forbion Capital Partners · Gilde Healthcare · HealthCap · Bioqube Ventures	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

SynOx Therapeutics website traffic

Latest recorded traffic for SynOx Therapeutics is 2.7K monthly website visits, up 92.9% over the last three months. SynOx Therapeutics's team grew 14.3% over the past year.

Latest monthly visits2.7K 3-month web change+92.9% 1-year team growth+14.3%

Monthly website visitsJan 2021–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
STStablix TherapeuticsStablix \| Protein Stabilization Therapeutics	New York City, United States	Operational	16	$78M	$252M
AIAffinité InstrumentsDeveloping ultra-compact, label-free sensing technology integrated into flexible bioanalytical devices for protein interaction analysis in diverse settings	Montreal, Canada	Operational
SBSibylla BiotechFacing the complexity of drug discovery with the power of an innovative approach for meeting unmet medical needs	Bresso, Italy	Operational
MAMassMatrixMass-spectrometry data analysis software for biologics research and development	Columbus, United States	Operational
AVAVECTASExcelling beyond	Maynooth, Ireland	Operational
RSResonant SensorsRapid benchtop antibody discovery with the ResoSens Ultra-Mab Pro. Providing high-throughput, label-free characterization for screening and assays	Arlington, United States	Operational
PBProxima BioFormerly VantAI. Proximity therapeutics hijacking cellular machinery for protein degradation	New York City, United States	Operational
PBProtego BioProtein stabilizing therapies targeting misfolding diseases	San Diego, United States	Operational